TOGETHER WE REACH




DEPARTMENT OF PATHOLOGY

Molecular Diagnosis of Gastroenteritis/Acute Diarrhea

Marc Roger Couturier, Ph.D., D(ABMM)



Assistant Professor of Pathology ARUP Medical Director: Microbial Immunology Parasitology & Fecal Testing Infectious Disease Rapid Testing



TOGETHER WE REACH



DEPARTMENT OF PATHOLOGY

Relevant Disclosures

• Biofire Diagnostics Inc.



Objectives

- 1. Discuss the epidemiology of acute diarrheal illness & approach to testing
- 2. Explore the new molecular panel-based methods and their potential role
- 3. Consider the incorporation of new diagnostic methods in clinical practice

DISCLAIMER This talk is meant to be provocative and empower the audience to consider various viewpoints and approaches to the diagnosis of acute diarrhea in the setting of molecular multiplex methodologies... There is no "right answer" at this time

TOGETHER WE REACH



DEPARTMENT OF PATHOLOGY

Acute diarrhea

What do we routinely test for?

– Bacteria

- Parasites

Viruses





TOGETHER WE REACH




Acute diarrhea


What is the actual prevalence

– Viruses

- Bacteria
- Parasites



DEPARTMENT OF PATHOLOGY





Acute Diarrheal illness

- Most acute GI infections are not reported or intervened medically in the USA¹
 - Cause significant morbidity and mortality
 - More significant in developing nations
 - Prevent dehydration, provide rehydration
 - CDC estimates >350 million acute diarrheal illnesses annually²
 - FoodNet reports 48 million are foodborne
 - Comprehensive U.S. epidemiological reports are lacking



Consider some facts

1. Viruses - most prevalent; least tested¹

- Norovirus is #1 GI infection in the USA
- Rotavirus declined 67% since vaccine introduction in USA

2. Bacteria - stool Cx are most common test

only positive 1-5% of cases²

3. Parasites - domestically acquired infections typically associated with defined exposure risks



GI pathogens in community onset/primary care setting

- Viral #1 cause of acute diarrhea
 norovirus
- Bacterial outbreak/cluster related
 Clostridium difficile is growing



• Parasitic – sporadic, low incidence



GI pathogens in hospitalized patients

- Common HAI in acute care & ICU
 - Viral norovirus, rotavirus
 - Rare/emerging sapovirus, adenovirus, astrovirus
 - Bacterial Clostridium difficile
 - Rare Salmonella



– Parasitic – very rare



In Practice

What is a common stool test ordering pattern for acute diarrhea?

- Stool Cx
- Single O&P
- <u>No viral tests</u>***




*** (based on composite ordering pattern data from ARUP and other large academic medical centers)




Viral testing

- Antigen detection EIA
 - Standard for rotavirus & adenovirus 40/41
 - Sensitivity and specificity are good vs electron microscopy
 - <u>Underutilized</u>
- PCR: available for norovirus
 - Better sensitivity and specificity than EIA¹
 - The way of the future for others
- No testing available for sapovirus & astrovirus



Bacterial testing

- Culture
 - Sensitivity: highly variable / excellent specificity
 - TAT: 24-96+ hours
 - Many labs use different combinations of media...can become costly
- Clostridium difficile real-time PCR
 - <u>Multiple</u> FDA approved methods
 - Fast, sensitive, and specific
 - Expensive, but most robust method







Protozoal testing

Overutilized O&P exams


Highly variable sensitivity

- Standard O&P does <u>NOT</u> readily detect:
 - Cryptosporidium spp.
 - Cyclospora spp.
 - Cystoisospora spp.
 - Microsporidia

UNIVERSITY

OF UTAH"

- 3+ specimens recommended/patient
 - Rarely received






TOGETHER WE REACH



DEPARTMENT OF PATHOLOGY

DFA or Antigen detection

- Giardia and Cryptosporidium
 - Recommended for initial screen
 - Rapid TAT and good sensitivity and specificity
- <u>Underutilized</u> when indicated in documented outbreaks¹





The answer to ALL our diarrheal testing needs...or not?

MULTIPLEX MOLECULAR DIAGNOSTICS



Why do we need multiplex detection?

- Syndromes too similar to separate clinically
- Lack of standardized/differential driven ordering for all appropriate diarrheal agents
 - Cx, too many O&P's, & no viral tests



Molecular testing considerations

- Abundant organisms
 - less focus on analytical sensitivity
 - Are these significantly better than what we have?
- Not appropriate in every patient
 - TAT fast enough to influence care decisions?
 - Will having these results influence clinical care?
 - Most viral/bacterial infections are self-limiting & supportive care is key

TOGETHER WE REACH



DEPARTMENT OF PATHOLOGY

Molecular testing considerations

- Cost may be <u>significant</u> limiting factor
 - Who pays for this (outpatients)?
 - How do we bill for this?
 - Per target? No CPT codes yet...



- Should large panels be standard?
 - Use mini-panels based on prevalence?
 - Viral first to cover the majority





FDA cleared testing approaches**

- Prodesse[®] Progastro[™] SSCS
- BD MaxTM Enteric Bacterial Panel
- Nanosphere Inc. Verigene® Enteric Pathogen test
- Luminex[™] xTAG Gastrointestinal Pathogen Panel (GPP)
- Biofire Diagnostics Inc. FilmArray[®] GI panel



Tests for bacteria only







BD MaxTM enteric bacterial panel

- Salmonella
- Shigella
- Campylobacter
- Shiga-like Toxin producing *E. coli* (STEC) stx1/stx2

UNIVERSITY OF UTAH[™]

DEPARTMENT OF PATHOLOGY

Verigene[®] Enteric Pathogens

Bacteria

- Campylobacter spp.
- Salmonella spp.
- Shigella spp.
- Vibrio spp.
- Yersinia enterocolitica
- Shiga toxin 1 and 2

Viruses

- Norovirus
- Adenovirus
- Rotavirus



TOGETHER WE REACH

THE UNIVERSITY OF UTAH[™]

$Luminex^{TM} \ {}_{xTAG \ GPP}$



OO

Luminex

×

DEPARTMENT OF PATHOLOGY

Bacteria

- Salmonella
- Shigella
- Campylobacter
- Clostridium difficile Toxin A/B
- Enterotoxigenic E. coli (ETEC) LT/ST
- *E. coli* O157
- Shiga-like Toxin producing E. coli (STEC) stx1/stx2

Viruses

- Rotavirus A
- Norovirus GI/GII

Parasites

- Giardia
- Cryptosporidium

FilmArray[®] GI Panel



Bacteria

THE

UNIVERSITY

OF UTAH[™]

- ETEC
- EPEC
- STEC/EHEC
- STEC 0157 serotype
- EIEC
- EAEC
- Vibrio spp.
- V. cholerae
- Shigella spp.
- S. dysenteriae
- Salmonella spp.
- Campylobacter spp.
- Yersinia enterocolitica
- Clostridium difficile
- Aeromonas spp.
- Plesiomonas shigelloides

Viruses

- Norovirus (GI, GII & GIV)
- Adenovirus F 40/41
- Rotavirus (A, B, C)
- Astrovirus
- Sapovirus

Parasites

- Cryptosporidium spp.
- Giardia lamblia
- Entamoeba histolytica
- Cyclospora cayetanensis



But do we really need ALL of this on each patient?

CONSIDER YOUR HOST



Hospitalized patients...maybe not

- Do you need to test for everything?
 - norovirus PCR
 - C. difficile PCR



- No FDA cleared norovirus PCR
 - LDTs reference lab or PHL lab support
 - EIA is FDA cleared: not recommended for routine testing (50% sensitivity) → reflex to PCR



Return traveler...maybe so

- Chronic diarrhea
 - Parasites likely depending on exposures; therapy likely indicated¹
 - Also consider O&P's for helminths or other protozoa
 - e.g. Balantidium coli, Dientamoeba fragilis, Cystoisospora, Cyclospora
 - Molecular doesn't cover everything!
- Bacterial causes are highly variable
 - Vibrio, Campylobacter, Shigella dysenteriae, Salmonella typhi, ETEC, EAggEC
 - If ongoing symptoms, treatment may be considered
 - Empiric therapy for ETEC is standard¹



Immunocompromised hosts...maybe so

- Pathogens not consistent in each group
- Patients typically receive extensive work-up
 More likely to have interventions in care¹
 - HIV+
 - Primary immunodeficiency

Viruses, *C. diff, Campy, Shigella, Salmonella, E. coli, Giardia, Crypto,* Microsporidia

- Solid organ transplant
- Stem cell transplant

Most diarrhea is NOT infectious Viruses (noro), *C. diff* Microsporidia



Healthy pediatric patients...maybe so

- Viral is most common¹
 - Norovirus rising, rotavirus declining (in vaccinated countries)
 - Adenovirus, sapovirus, astrovirus also significant
- *C. difficile* on the rise in non-infants²
- Exposures that adults don't typically have
 - <u>excessive</u> fecal-oral exposures (daycares)³
- Likely actionable changes to management based on severity^{3,4}
 - Guidelines do not recommend treating all pediatric gastrointestinal infections with antibiotics





Primary care/community...maybe not

- Lower potential for intervention in care
 - Most will not require treatment
- Long TAT due to transport to central lab/reference lab
 - Utility is lost after several days (see Cx & O&P)¹
 - Viral is #1...symptoms will likely resolve
 - Resolved symptoms but outstanding bill
- Should you even test?



Complicated outpatient...maybe so

- Advanced age >65
 - Salmonella & Campylobacter likely treated¹
- Comorbidities
 - e.g. Heart disease, aortic graft, diabetes, chronic kidney disease
- Dysentery or blood in stool
 - Knowing STEC can be critical (no Abx) vs invasive Salmonella/Shigella/Campy (+/- Abx)
- Duration of illness
 - >14 days = persistent...more likely parasitic or Microsporidia
 - Treatment often indicated

THE UNIVERSITY OF UTAH[™]

DEPARTMENT OF PATHOLOGY

Outpatient use & outbreak identification?

- Observed cluster/suspected outbreak of unknown/unpredictable origin
 - Cyclospora with imported produce (2013 & 2014)¹
 - Campylobacter in Alaskan snow peas (2011)²
 - STEC in cookie dough (2009)³
 - Sapovirus (2002-2009)⁴
- Once N=? cases confirmed, perform directed testing with classical methods first?
 - Cost containment
 - Are the previous methods good enough here?



Implementation

- Assays are expensive; cost effective implementation often involves cessation of Cx
 - Will the lab maintain selective media for specific isolation of pathogens?
 - No Cx = No AST capabilities when needed
- But...smaller laboratories may replace Cx completely
 - FDA cleared molecular assay performed according to package insert is better than a poorly performed classical test
 - Campylobacter Cx variability nationwide: Cx time, transport conditions, atmosphere, plated media^{1,2}
 - ...performing O&P for Cryptosporidium, Cyclospora



Public Health Concerns

- Culture independent assays = 1 positives
 - Are PHLs ready?
 - Who does the culture (who pays)?
 - What if we have no isolates...
 - Can you EVEN culture the specimens?
 - Luminex No
 - BD Max & Prodesse Maybe
 - Biofire, Verigene Yes



Timeline of an STEC outbreak investigation

Day 0: STEC isolate identified at (3-10 days post ingestion) Day 1-7: PHL receives strain and performs typing & fingerprinting Day 8-12: PHL reports case with appropriate outbreak information Total time: 2-3 weeks from exposure...WITH an isolate

What happens without isolates...

Bigger outbreaks? Incomplete reporting? Underestimates of outbreak sizes?

Alternatively, panel tests may identify outbreaks better upfront...and direct culturing efforts

Conversations with PHL are imperative BEFORE implementation

http://www.cdc.gov/ecoli/reporting-timeline.html



Coming full circle

- Panel-based GI testing is here to stay
- Not all patients likely need this testing
- Consider:
 - Cost
 - Influence (if any) on care decisions
 - Adequacy of prior methods
 - Pre-test probability of a pathogen
- Cost-effectiveness studies are needed to guide us!
- Talk to your PHL sooner than later



